Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs